270 related articles for article (PubMed ID: 19378852)
1. Treatment of deep vein thrombosis with continuous intravenous infusion of LMWH in children--an alternative to subcutaneous application when needed.
Blatný J; Fiamoli V
Vnitr Lek; 2009 Mar; 55(3):227-32. PubMed ID: 19378852
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis.
Lopaciuk S; Bielska-Falda H; Noszczyk W; Bielawiec M; Witkiewicz W; Filipecki S; Michalak J; Ciesielski L; Mackiewicz Z; Czestochowska E; Zawilska K; Cencora A
Thromb Haemost; 1999 Jan; 81(1):26-31. PubMed ID: 9974369
[TBL] [Abstract][Full Text] [Related]
4. The home treatment of deep vein thrombosis with low molecular weight heparin, forced mobilisation and compression.
Labas P; Ohrádka B; Vladimír J; Cambal M
Int Angiol; 2000 Dec; 19(4):303-7. PubMed ID: 11305727
[TBL] [Abstract][Full Text] [Related]
5. Low molecular weight heparin for deep vein thrombosis in glioma patients.
Schmidt F; Faul C; Dichgans J; Weller M
J Neurol; 2002 Oct; 249(10):1409-12. PubMed ID: 12382158
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy.
Narin C; Reyhanoglu H; Tülek B; Onoglu R; Ege E; Sarigül A; Yeniterzi M; Durmaz I
Adv Ther; 2008 Jun; 25(6):585-94. PubMed ID: 18568442
[TBL] [Abstract][Full Text] [Related]
7. Home therapy with LMWH in deep vein thrombosis: randomized study comparing single and double daily administrations.
Bellosta R; Ferrari P; Luzzani L; Carugati C; Cossu L; Talarico M; Sarcina A
Angiology; 2007; 58(3):316-22. PubMed ID: 17626986
[TBL] [Abstract][Full Text] [Related]
8. [Current trends in the treatment of deep venous thrombosis].
Eichlisberger R; Frauchiger B; Jäger K
Schweiz Rundsch Med Prax; 1994 Feb; 83(7):183-8. PubMed ID: 8184243
[TBL] [Abstract][Full Text] [Related]
9. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects.
Scheuch G; Brand P; Meyer T; Herpich C; Müllinger B; Brom J; Weidinger G; Kohlhäufl M; Häussinger K; Spannagl M; Schramm W; Siekmeier R
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):603-14. PubMed ID: 18204174
[TBL] [Abstract][Full Text] [Related]
10. Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients.
Mazokopakis EE; Vrentzos GE; Ganotakis ES
Curr Med Res Opin; 2003; 19(6):565-6. PubMed ID: 14594529
[TBL] [Abstract][Full Text] [Related]
11. Low-molecular-weight heparin in pediatric patients.
Sutor AH; Chan AK; Massicotte P
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():31-9. PubMed ID: 15085464
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Michaels LA; Gurian M; Hegyi T; Drachtman RA
Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
[TBL] [Abstract][Full Text] [Related]
13. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT).
Bratt G; Aberg W; Johansson M; Törnebohm E; Granqvist S; Lockner D
Thromb Haemost; 1990 Dec; 64(4):506-10. PubMed ID: 1964751
[TBL] [Abstract][Full Text] [Related]
14. Low molecular weight heparin suppresses tumor necrosis factor expression from deep vein thrombosis.
Carr JA; Cho JS
Ann Vasc Surg; 2007 Jan; 21(1):50-5. PubMed ID: 17349336
[TBL] [Abstract][Full Text] [Related]
15. Treatment of deep vein thrombosis with low-molecular-weight heparins: a consensus statement of the Gesellschaft für Thrombose-und Hämostaseforschung (GTH).
Harenberg J; Schmitz-Huebner U; Breddin KH; Hass S; Heinrich F; Heinrichs C; Kienast J; Roebruck P; Theiss W; Wenzel E
Semin Thromb Hemost; 1997; 23(1):91-6. PubMed ID: 9156416
[TBL] [Abstract][Full Text] [Related]
16. [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis].
Moreno-Palomares JJ; Fisac-Herrero RM; Herrero-Domingo A; Ferreira-Pasos EM; Grasa J; Reverte-Cejudo D
An Med Interna; 2001 Jul; 18(7):364-8. PubMed ID: 11534421
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulants in the treatment of deep vein thrombosis.
Merli G
Am J Med; 2005 Aug; 118 Suppl 8A():13S-20S. PubMed ID: 16125510
[TBL] [Abstract][Full Text] [Related]
18. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
Stricker H; Marchetti O; Haeberli A; Mombelli G
Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
[TBL] [Abstract][Full Text] [Related]
19. Continuous administration of heparin in patients with deep vein thrombosis can increase plasma levels of diamine oxidase.
Klocker J; Perkmann R; Klein-Weigel P; Mörsdorf G; Drasche A; Klingler A; Fraedrich G; Schwelberger HG
Vascul Pharmacol; 2004 Jan; 40(6):293-300. PubMed ID: 15063833
[TBL] [Abstract][Full Text] [Related]
20. DVT treatment in 2000: state of the art.
Davidson BL
Orthopedics; 2000 Jun; 23(6 Suppl):s651-4. PubMed ID: 10875431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
